Literature DB >> 20153804

Pituitary senescence: the evolving role of Pttg.

Vera Chesnokova1, Shlomo Melmed.   

Abstract

Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation. Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation. In vivo senescence is an important protective mechanism against cancer. Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas. Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy. Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways. Abundant PTTG in GH-secreting pituitary adenomas also triggers p21-dependent senescence. Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth. These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153804      PMCID: PMC2906651          DOI: 10.1016/j.mce.2010.02.012

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  58 in total

Review 1.  gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways.

Authors:  E Arzt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  Telomeres, aging and cancer: in search of a happy ending.

Authors:  Sahn-ho Kim Sh; Patrick Kaminker; Judith Campisi
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

3.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

4.  Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes.

Authors:  Zhiyong Wang; Enrico Moro; Kalman Kovacs; Run Yu; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

5.  Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division.

Authors:  Z Wang; R Yu; S Melmed
Journal:  Mol Endocrinol       Date:  2001-11

Review 6.  Cellular senescence as a tumor-suppressor mechanism.

Authors:  J Campisi
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

7.  A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.

Authors:  Clemens A Schmitt; Jordan S Fridman; Meng Yang; Soyoung Lee; Eugene Baranov; Robert M Hoffman; Scott W Lowe
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

Review 8.  Molecular defects in the pathogenesis of pituitary tumours.

Authors:  Andy Levy; Stafford Lightman
Journal:  Front Neuroendocrinol       Date:  2003-04       Impact factor: 8.606

Review 9.  Epigenetic change in pituitary tumorigenesis.

Authors:  W E Farrell; R N Clayton
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

10.  Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence.

Authors:  Masashi Narita; Sabrina Nũnez; Edith Heard; Masako Narita; Athena W Lin; Stephen A Hearn; David L Spector; Gregory J Hannon; Scott W Lowe
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

View more
  17 in total

Review 1.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas.

Authors:  Lisiane Cervieri Mezzomo; Paulo Henrique Gonzales; Frederico Giacomoni Pesce; Nélson Kretzmann Filho; Nelson Pires Ferreira; Miriam Costa Oliveira; Maria Beatriz Fonte Kohek
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

3.  Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.

Authors:  Emilija Manojlovic-Gacic; Milica Skender-Gazibara; Vera Popovic; Ivan Soldatovic; Novica Boricic; Savo Raicevic; Sandra Pekic; Mirjana Doknic; Dragana Miljic; Irina Alafuzoff; Fredrik Pontén; Olivera Casar-Borota
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

4.  Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial-mesenchymal transition (EMT) in SCC15 cells.

Authors:  Enjiao Zhang; Shuang Liu; Zhongfei Xu; Shaohui Huang; Xuexin Tan; Changfu Sun; Li Lu
Journal:  Tumour Biol       Date:  2014-05-31

Review 5.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

6.  MGMT expression and pituitary tumours: relationship to tumour biology.

Authors:  Ann McCormack; Warren Kaplan; Anthony J Gill; Nicholas Little; Raymond Cook; Bruce Robinson; Roderick Clifton-Bligh
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

7.  Altered expression of securin (Pttg1) and serpina3n in the auditory system of hearing-impaired Tff3-deficient mice.

Authors:  M Lubka-Pathak; A A Shah; M Gallozzi; M Müller; U Zimmermann; H Löwenheim; M Pfister; M Knipper; N Blin; T Schimmang
Journal:  Cell Mol Life Sci       Date:  2010-11-15       Impact factor: 9.261

8.  Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.

Authors:  Jhen-Wei Ruan; Yi-Chu Liao; Ingrid Lua; Ming-Hsun Li; Chih-Yi Hsu; Ji-Hshiung Chen
Journal:  Breast Cancer Res       Date:  2012-07-12       Impact factor: 6.466

9.  Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling.

Authors:  Y C Liao; J W Ruan; I Lua; M H Li; W L Chen; J R Y Wang; R H Kao; J H Chen
Journal:  Oncogene       Date:  2011-10-17       Impact factor: 9.867

Review 10.  Progress in the Diagnosis and Classification of Pituitary Adenomas.

Authors:  Luis V Syro; Fabio Rotondo; Alex Ramirez; Antonio Di Ieva; Murat Aydin Sav; Lina M Restrepo; Carlos A Serna; Kalman Kovacs
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.